Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NextGen Bioscience has said that it is in collaboration negotiations with Warburg Glycomed, a biopharmaceutical firm that has developed a new class of drugs which has shown potent anticancer properties in animal models.
Subscribe to our email newsletter
Warburg Glycomed has expressed keen interest in collaborating with NextGen in a recently signed letter of intent, and is confident that a mutually beneficial deal can be arranged.
Konstantinos Kardiasmenos, CEO of NextGen, said: “These collaboration discussions with Warburg Glycomed represent progress on fulfilling our business goal to form international collaboration agreements with specialty research organisations. An alliance with Warburg would strengthen both companies’s position to capture the phenomenal global market for therapeutic cancer agents.”